semaglutide bimagrumab + plus alone or in combination for the treatment of obesity: a randomized phase 2 trial Next-Generation Myostatin Inhibitors: Bimagrumab, Trevogrumab, – Researchers to share weight loss

Consequently, the creation of fertility-preserving agents that target chemotherapy-induced oxidative stress and ferroptosis has the potential to mitigate ovarian damage and enhance the overall wellbeing of individuals with cancer

MENLO PARK, Calif., May 7, 2025 /PRNewswire/ -- Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, in partnership with Mayo Clinic researchers, presented new findings at Digestive Disease Week (DDW) 2025 showing its proprietary machine-learning algorithms can predict which patients are more likely to experience side effects, specifically nausea, from GLP-1 therapies

If you want a needle-free, evidence-backed path to weight loss, the actionable starting point is a physician-supervised GLP-1 program

( [ \- Link Opens in New Tab]( 07

This medication, a GLP-1 receptor agonist, mimics the hormone GLP-1 to help regulate blood sugar levels and reduce appetite

BioFactors, 42(6), 647-664